Shenzhen Kangzhe Biotechnology Co., Ltd.

This study tests a new capsule (CMS-D002) to see if it can reduce heavy menstrual bleeding in women with uterine fibroids. About 120 women aged 18-50 will take either the capsule or a placebo daily for 12 weeks. The main goal is to see if the treatment lowers blood loss to a norm…

This early-stage study tests a new drug called CMS-D017 in 88 healthy adults to see if it is safe and how the body processes it. The drug is being developed for two rare blood and kidney diseases. Participants receive either the drug or a placebo, and researchers monitor side eff…